Liver Failure/Cirrhosis/Portal Hypertension

You have full text access to this OnlineOpen article

L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure†‡

  1. Lars Marius Ytrebø1,§,*,
  2. Rune Gangsøy Kristiansen1,
  3. Hanne Mæhre2,
  4. Ole Martin Fuskevåg3,
  5. Trine Kalstad4,
  6. Arthur Revhaug4,
  7. María Jover Cobos5,
  8. Rajiv Jalan6,¶,*,
  9. Christopher F. Rose7,*

Article first published online: 18 FEB 2009

DOI: 10.1002/hep.22917

Issue

Hepatology

Hepatology

Volume 50, Issue 1, pages 165–174, July 2009

Additional Information

How to Cite

Ytrebø, L. M., Kristiansen, R. G., Mæhre, H., Fuskevåg, O. M., Kalstad, T., Revhaug, A., Cobos, M. J., Jalan, R. and Rose, C. F. (2009), L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology, 50: 165–174. doi: 10.1002/hep.22917

Author Information

  1. 1

    Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, Norway

  2. 2

    Institute of Marine Biotechnology, University of Tromsø, Norway

  3. 3

    Department of Clinical Pharmacology, University Hospital of North Norway and University of Tromsø, Norway

  4. 4

    Department of Digestive Surgery, University Hospital of North Norway and University of Tromsø, Norway

  5. 5

    Unit for Clinical Management of Digestive Diseases-CIBERehd, Hospital Universitario de Valme, Seville, Spain

  6. 6

    Liver Failure Group, Institute of Hepatology, University College London Medical School, UK

  7. 7

    Neuroscience Research Unit, Hôpital Saint-Luc (CRCHUM), Université de Montréal, Québec, Canada

  1. §

    fax: +47 776 26192

  2. fax: +44 207 3800405

*Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, N-9038 Tromsø, Norway

  1. †

    Potential conflict of interest: University College London has filed for patents surrounding the use of L-Ornithine and Phenylacetate/Phenylbutyrate for the treatment of hepatic encephalopathy, which has been licensed to Ocera Therapeutics.

  2. ‡

    See Editorial on Page 3

Publication History

  1. Issue published online: 23 JUN 2009
  2. Article first published online: 18 FEB 2009
  3. Accepted manuscript online: 18 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 9 FEB 2009
  5. Manuscript Received: 6 MAY 2008

Funded by

  • Norwegian Research Council
  • Helse Nord
  • Fonds de Recherche en Santé du Quebec (FRSQ, Canada)
  • University College London Business

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (900K)

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_22917_sm_SupDoc.doc39KSupplementary Information
HEP_22917_sm_SupFig1.tif53KSupplementary Figure 1.
HEP_22917_sm_SupTab1.doc25KSupplementary Table 1. Glutamine and ornithine levels in arterial blood, muscle, and brain at t=8hrs in pigs with ALF treated with O (n=3) and P (n=3).

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (900K)